DGAP-News

STRATEC reports consistent growth in first nine months of 2014

DGAP-News: STRATEC Biomedical AG / Key word(s): Quarter
Results/Interim Report
STRATEC reports consistent growth in first nine months of 2014

22.10.2014 / 07:32

---------------------------------------------------------------------

STRATEC reports consistent growth in first nine months of 2014

- Sales of EUR 105.3 million in 9M/2014
(+15.9%; 9M/2013: EUR 90.8 million)
- EBIT of EUR 17.7 million** in 9M/2014
(+37.7%; 9M/2013: EUR 12.8 million)
- EBIT margin of 16.8%** in 9M/2014
(+270 base points; 9M/2013: 14.1%)
- Consolidated net income of EUR 14.6 million** in 9M/2014
(+43.8%; 9M/2013: EUR 10.2 million)
- Earnings per share of EUR 1.24** in 9M/2014
(+42.5%; 9M/2013: EUR 0.87)
- Improved EBIT margin expectations


Birkenfeld, October 22, 2014

STRATEC Biomedical AG, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard,
TecDAX) today announced its results for the period January 1, 2014 to
September 30, 2014 upon the publication of its Interim Report as of
September 30, 2014.

Key figures (EUR 000s)             01.01.-           01.01.-        Changes

                                09.30.2014       09.30.2013*

Sales                              105,278            90,819         +15.9%

EBIT                              17,685**            12,847         +37.7%

EBIT margin (%)                     16.8**              14.1       +270 BPS

Consolidated net income           14,627**            10,173         +43.8%

Earnings per share (EUR)            1.24**              0.87         +42.5%

* The accounting methods used in the consolidated financial statements were
amended in line with IAS 8 in the 2013 financial year. Reference is made in
this respect to the information in the Annual Report 2013 in Section A of
the notes to the consolidated financial statements.

** 2014 figure adjusted to exclude a one-off negative item resulting from
recognition in the first quarter of expenses for the remaining years of the
term of a management board contract for a retired member of the Board of
Management and a positive non-operating item due to recognition of income
for a development project discontinued in 2013. Unadjusted EBIT amounts to
EUR 17.0 million, the corresponding EBIT margin amounts to 16.2%,
consolidated net income to EUR 14.2 million and earnings per share to EUR
1.20. The actual amount of the aforementioned expense item may differ at
the time of payment from the amounts presented here.


Financial performance

STRATEC sustained the positive performance seen in the first half of the
year in the third quarter of 2014. Sales increased by 15.9% to EUR 105.3